The U.S. Food and Drug Administration has approved a new dose of the GLP-1 class weight loss drug Wegovy that’s three times the size of the previous maximum dose.
Known as “Wegovy HD,” the new doses of the semaglutide drug are 7.2 milligrams, compared to 2.4-milligram doses that were approved for chronic weight management in June 2021.
-copy-29e15046.jpeg?w=600)
